ACE Private Equity Invests in Danish Drug Ingredient Maker Chr. Olesen Synthesis

PUBT · 1d ago
ACE Private Equity Invests in Danish Drug Ingredient Maker Chr. Olesen Synthesis
  • ACE Private Equity invested in Chr. Olesen Synthesis in an acquisition led by Samfara, announced Nov. 17, 2026.
  • Denmark-based Olesen manufactures controlled-substance active pharmaceutical ingredients used primarily in opioid addiction and ADHD treatments for generic drugmakers globally.
  • Growth opportunities include expanding production capacity, launching adjacent products and pursuing selective acquisitions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ace & Company SA published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.